Alex Parker

Alex Parker is a seasoned professional in the biotech and healthcare sectors, currently serving as a Board Member at Paige and as a Member of the Board of Directors for Genome Medical, Precede Biosciences, Franklin Land Trust, and Exai Bio. Additionally, Alex holds strategic advisor roles at Universal Diagnostics S.A., Casdin Capital, LLC, Earli Inc., and Function Oncology. Board involvement extends to C2i Genomics, reflecting extensive expertise in leadership and governance. Academic credentials include a PhD in Molecular Genetics from the University of Maine and a BS in Philosophy and Biology from The University of New Mexico.